Table 4.

Univariate and multivariate survival analyses for propensity-score-matching cohort (n = 42).

	Progression-Free Survival				Overall Survival
	Univariate		Multivariate		Univariate
Characters	HRs (95% CI)	p	HRs (95% CI)	p	HRs (95% CI)	p
Age (≥50 vs. <50)	0.456 (0.13–1.57)	0.21	-	-	1.62 (0.29–8.97)	0.58
Menopause (yes vs. no)	0.69 (0.21–2.27)	0.54	-	-	4.17 (0.49–35.76)	0.19
Hormone Receptor (+ vs. −)	0.15 (0.03–0.71)	0.02	0.07 (0.01–1.07)	0.06	0.16 (0.02–1.37)	0.09
Her-2 (+ vs. −)	2.26 (0.69–7.45)	0.18	-	-	1.99 (0.40–9.91)	0.40
Tumor size (>5 vs. >2 vs. ≤2)	3.36 (1.26–8.97)	0.02	1.75 (0.54–5.74)	0.35	3.33 (0.85–13.07)	0.08
Lymph node involvement (yes vs. no)	10.29 (1.31–80.73)	0.03	4.18 (0.41–43.03)	0.23	5.07 (0.59–43.70)	0.14
Molecular subtype (TNBC vs Her-2 vs. Hormone Receptor+)	1.99 (1.01–3.92)	0.05	0.46 (0.09–2.43)	0.36	2.07 (0.81– 5.30)	0.13
Stage (III/IV vs. 0/I/II)	4.73 (1.38–16.19)	0.01	1.76 (0.35–8.84)	0.49	4.99 (0.91–27.26)	0.06
HIV (yes vs. no)	8.26 (1.64–41.66)	0.01	6.83 (1.22–38.12)	0.03	322.47 (0.04–2,563,794.24)	0.21

HRs: hazard ratios; CI: confidence intervals.